Agilent Technologies Inc. (NYSE: A) today introduced two new assays for the 2200 TapeStation system: the RNA ScreenTape and the D1000 ScreenTape assays. Both assays are essential for the quality control of samples in next-generation sequencing (NGS) workflow. They replace Agilent’s R6K and D1K ScreenTape assays.
The new RNA ScreenTape assay delivers qualitative and quantitative assessment of total RNA for both eukaryotic and prokaryotic samples, with a Bioanalyzer-like electropherogram and RNA Integrity Number equivalent (RIN e) quality score. The new D1000 ScreenTape assay builds on the success of the D1K ScreenTape, with closer alignment in sizing and quantification to the market-leading 2100 Bioanalyzer system.
“Next-generation sequencing has become an invaluable tool for life science researchers, and the key to achieving the highest-quality NGS results is the ability to monitor and ensure the quality of samples being prepared throughout the front-end process,” said Yvonne Linney, vice president and general manager of Agilent’s Life Science Solutions Division. “The 2200 TapeStation system is an ideal technology for this, providing a simplified, automated process for nucleic acid quality control. With enhanced performance, these new assays optimize quantification and sizing and improve RNA resolution.”
For more information about the new Agilent RNA ScreenTape and D1000 ScreenTape assays visit www.agilent.com/genomics/NGS-QC.About Agilent Technologies Agilent Technologies Inc. (NYSE: A) is the world’s premier measurement company and a technology leader in chemical analysis, life sciences, diagnostics, electronics and communications. The company’s 20,600 employees serve customers in more than 100 countries. Agilent had revenues of $6.8 billion in fiscal 2013. Information about Agilent is available at www.agilent.com. On Sept. 19, 2013, Agilent announced plans to separate into two publicly traded companies through a tax-free spinoff of its electronic measurement company. The separation is expected to be completed in early November 2014.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV